The pharmaceutical industry got off relatively easy in the Affordable Care Act. It accepted approximately $80 billion in cuts, while holding off policies like direct drug negotiation and re importation that would have undermined profits. Now, John Castellani — the head of the industry’s lobbying group PhRMA — reassures Kaiser Health News that the industry made the “right decision” to support reform, despite the blacklash it generated among Republicans. The industry is now warning lawmakers that any additional cuts that may be included in the debt ceiling negotiations would lead to job losses.
PhRMA Sure It Made ‘Right Decision’ To Support Health Reform, Accept $80 Billion In Cuts